Department of Ophthalmology, School of Medicine, College of Health Sciences, Addis Ababa University, P.O. Box 9086, Addis Ababa, Ethiopia.
Child Health Evaluative Sciences Program and Centre for Global Child Health, SickKids Research Institute, Toronto, Canada.
BMC Ophthalmol. 2023 May 23;23(1):231. doi: 10.1186/s12886-023-02980-8.
Retinoblastoma is the most frequent intraocular malignancy of the eye in children, occurring in early childhood. Based on global estimates, Ethiopia is expected to observe over 200 new retinoblastoma cases per year, however without a cancer registry, this number is difficult to confirm. Therefore, the goal of the study was to determine the incidence and geographic distribution of retinoblastoma in Ethiopia.
A retrospective medical chart review of clinically diagnosed new retinoblastoma patients between January 1, 2017 - December 31, 2020, in four public Ethiopian tertiary hospitals was performed. The incidence of retinoblastoma was calculated by a birth-cohort analysis.
There were 221 retinoblastoma patients observed in the study period. The incidence of retinoblastoma was found to be 1 in 52,156 live births. Incidence varied among different regions of Ethiopia.
The incidence of retinoblastoma observed in this study is likely an underestimate. It is possible that patients were undercounted because they were seen outside of the 4 main retinoblastoma treatment facilities included in this facility, or they experienced barriers to accessing care. Our study suggests a need for a nationwide retinoblastoma registry and more retinoblastoma treatment centers in the country.
视网膜母细胞瘤是儿童期最常见的眼内恶性肿瘤,多发生于幼儿期。根据全球估计,埃塞俄比亚每年预计将有超过 200 例新的视网膜母细胞瘤病例,但由于没有癌症登记处,这个数字很难得到证实。因此,本研究的目的是确定埃塞俄比亚视网膜母细胞瘤的发病率和地理分布。
对 2017 年 1 月 1 日至 2020 年 12 月 31 日期间在埃塞俄比亚四家公立三级医院经临床诊断为新发视网膜母细胞瘤的患者进行回顾性病历审查。采用出生队列分析计算视网膜母细胞瘤的发病率。
研究期间共观察到 221 例视网膜母细胞瘤患者。视网膜母细胞瘤的发病率为每 52156 例活产儿中 1 例。发病率在埃塞俄比亚不同地区有所不同。
本研究观察到的视网膜母细胞瘤发病率可能被低估。可能是因为患者在包括在本研究中的 4 家主要视网膜母细胞瘤治疗机构之外的地方就诊,或者因为他们在获得治疗方面存在障碍,导致患者漏诊。我们的研究表明,该国需要建立一个全国性的视网膜母细胞瘤登记处和更多的视网膜母细胞瘤治疗中心。